Drug Free Solution, Inc.
DSOL
$0.0002
$0.000.00%
| 02/28/2014 | 11/30/2013 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -92.47% | |||
| Gross Profit | -- | 97.92% | |||
| SG&A Expenses | 25.18% | 700.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.28% | 151.49% | |||
| Operating Income | 3.68% | -147.33% | |||
| Income Before Tax | 3.68% | -147.33% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.68% | -147.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.68% | -147.33% | |||
| EBIT | 3.68% | -147.33% | |||
| EBITDA | 5.35% | -145.82% | |||
| EPS Basic | 8.33% | -100.00% | |||
| Normalized Basic EPS | 12.50% | -100.00% | |||
| EPS Diluted | 8.33% | -100.00% | |||
| Normalized Diluted EPS | 12.50% | -100.00% | |||
| Average Basic Shares Outstanding | 2.81% | 18.77% | |||
| Average Diluted Shares Outstanding | 2.81% | 18.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
